{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:09:06Z","timestamp":1794236946960,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovation Group Project of Shanghai Municipal Health Commission","award":["2019CXJQ03"],"award-info":[{"award-number":["2019CXJQ03"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"crossref","award":["202040045"],"award-info":[{"award-number":["202040045"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>DNA methylation-associated studies on biliary tract cancer (BTC), including cholangiocarcinoma (CCA) and gallbladder cancer (GBC), may improve the BTC classification scheme. We proposed to identify the shared methylation changes of BTCs and investigate their associations with genomic aberrations, immune characteristics, and survival outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Multi-dimensional data concerning mutation, DNA methylation, immune-related features, and clinical data of 57 CCAs and 48 GBCs from Eastern Hepatobiliary Surgery Hospital (EHSH) and 36 CCAs in the TCGA-CHOL cohort were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In our cohort including 24 intrahepatic CCAs (iCCAs), 20 perihilar CCAs (pCCAs), 13 distal CCAs (dCCAs), and 48 GBCs, 3369 common differentially methylated regions (DMRs) were identified by comparing tumor and non-tumor samples. A lower level of methylation changes of these common DMRs was associated with fewer copy number variations, fewer mutational burden, and remarkably longer overall survival (OS, hazard ratio [HR] = 0.07, 95% confidence interval [CI] 0.01\u20130.65, <jats:italic>P<\/jats:italic> = 0.017). Additionally, a 12-marker model was developed and validated for prognostication after curative surgery (HR = 0.21, 95% CI 0.10\u20130.43, <jats:italic>P<\/jats:italic> &lt; 0.001), which exhibited undifferentiated prognostic effects in subgroups defined by anatomic location (iCCAs, d\/pCCAs, GBCs), TNM stage, and tumor purity. Its prognostic utility remained significant in multivariable analysis (HR = 0.26, 95% CI 0.11\u20130.59, <jats:italic>P<\/jats:italic> = 0.001). Moreover, the BTCs with minimal methylation changes exhibited higher immune-related signatures, infiltration of CD8<jats:sup>+<\/jats:sup> lymphocytes, and programmed death-ligand 1 (PD-L1) expression, indicating an inflamed tumor immune microenvironment (TIME) with PD-L1 expression elicited by immune attack, potentially suggesting better immunotherapy efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In BTCs, DNA methylation is a powerful tool for molecular classification, serving as a robust indicator of genomic aberrations, survival outcomes, and tumor immune microenvironment. Our integrative analysis provides insights into the prognostication after curative surgery and patient selection for immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-021-02197-w","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T14:04:14Z","timestamp":1644242654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhiquan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"issue":"1","key":"2197_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol. 2020;73(1):170\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.007.","journal-title":"J Hepatol"},{"issue":"5","key":"2197_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959\u201369. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.009.","journal-title":"J Hepatol"},{"issue":"1","key":"2197_CR3","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5(1):5696. https:\/\/doi.org\/10.1038\/ncomms6696.","journal-title":"Nat Commun"},{"issue":"4","key":"2197_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cncr.31850","volume":"125","author":"RR Narayan","year":"2019","unstructured":"Narayan RR, Creasy JM, Goldman DA, Gonen M, Kandoth C, Kundra R, et al. Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations. Cancer. 2019;125(4):575\u201385. https:\/\/doi.org\/10.1002\/cncr.31850.","journal-title":"Cancer"},{"issue":"9","key":"2197_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003\u201310. https:\/\/doi.org\/10.1038\/ng.3375.","journal-title":"Nat Genet"},{"issue":"17","key":"2197_CR6","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0078.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2197_CR7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872\u20136. https:\/\/doi.org\/10.1038\/ng.3030.","journal-title":"Nat Genet"},{"issue":"10","key":"2197_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0368.","journal-title":"Cancer Discov"},{"issue":"5","key":"2197_CR9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/hep.30493","volume":"69","author":"B Goeppert","year":"2019","unstructured":"Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology. 2019;69(5):2091\u2013106. https:\/\/doi.org\/10.1002\/hep.30493.","journal-title":"Hepatology"},{"issue":"11","key":"2197_CR10","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18(11):2780\u201394. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.033.","journal-title":"Cell Rep"},{"issue":"6","key":"2197_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.trecan.2019.05.002","volume":"5","author":"CJ O\u2019Rourke","year":"2019","unstructured":"O\u2019Rourke CJ, Lafuente-Barquero J, Andersen JB. Epigenome remodeling in cholangiocarcinoma. Trends Cancer. 2019;5(6):335\u201350. https:\/\/doi.org\/10.1016\/j.trecan.2019.05.002.","journal-title":"Trends Cancer"},{"issue":"6","key":"2197_CR12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/hep.31585","volume":"73","author":"J Bragelmann","year":"2020","unstructured":"Bragelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, et al. Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer. Hepatology. 2020;73(6):2293\u2013310. https:\/\/doi.org\/10.1002\/hep.31585.","journal-title":"Hepatology"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijsu.2018.03.053","volume":"53","author":"JS Muhammad","year":"2018","unstructured":"Muhammad JS, Khan MR, Ghias K. DNA methylation as an epigenetic regulator of gallbladder cancer: an overview. Int J Surg. 2018;53:178\u201383. https:\/\/doi.org\/10.1016\/j.ijsu.2018.03.053.","journal-title":"Int J Surg"},{"issue":"7","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.trecan.2020.03.003","volume":"6","author":"PK Tiwari","year":"2020","unstructured":"Tiwari PK. Epigenetic biomarkers in gallbladder cancer. Trends Cancer. 2020;6(7):540\u20133. https:\/\/doi.org\/10.1016\/j.trecan.2020.03.003.","journal-title":"Trends Cancer"},{"issue":"5","key":"2197_CR15","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/ajco.13129","volume":"15","author":"K Baghel","year":"2019","unstructured":"Baghel K, Kazmi HR, Chandra A, Raj S, Srivastava RN. Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer. Asia Pac J Clin Oncol. 2019;15(5):e120\u2013e5. https:\/\/doi.org\/10.1111\/ajco.13129.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"2197_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812\u201330 e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"issue":"4","key":"2197_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jtho.2016.11.2235","volume":"12","author":"X Mao","year":"2017","unstructured":"Mao X, Zhang Z, Zheng X, Xie F, Duan F, Jiang L, et al. Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol. 2017;12(4):663\u201372. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2235.","journal-title":"J Thorac Oncol"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/978-1-4939-7481-8_20","volume":"1708","author":"J Wendt","year":"2018","unstructured":"Wendt J, Rosenbaum H, Richmond TA, Jeddeloh JA, Burgess DL. Targeted bisulfite sequencing using the SeqCap Epi Enrichment System. Methods Mol Biol. 2018;1708:383\u2013405. https:\/\/doi.org\/10.1007\/978-1-4939-7481-8_20.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2197_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41551-021-00746-5","volume":"5","author":"N Liang","year":"2021","unstructured":"Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T, et al. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021;5(6):586\u201399. https:\/\/doi.org\/10.1038\/s41551-021-00746-5.","journal-title":"Nat Biomed Eng"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fgene.2014.00324","volume":"5","author":"MD Robinson","year":"2014","unstructured":"Robinson MD, Kahraman A, Law CW, Lindsay H, Nowicka M, Weber LM, et al. Statistical methods for detecting differentially methylated loci and regions. Front Genet. 2014;5:324. https:\/\/doi.org\/10.3389\/fgene.2014.00324.","journal-title":"Front Genet"},{"issue":"1","key":"2197_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25\u20139. https:\/\/doi.org\/10.1038\/75556.","journal-title":"Nat Genet"},{"issue":"D1","key":"2197_CR22","doi-asserted-by":"publisher","first-page":"D419","DOI":"10.1093\/nar\/gky1038","volume":"47","author":"H Mi","year":"2019","unstructured":"Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47(D1):D419\u2013D26. https:\/\/doi.org\/10.1093\/nar\/gky1038.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2197_CR23","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"The Gene Ontology C","year":"2019","unstructured":"The Gene Ontology C. The Gene Ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330\u2013D8. https:\/\/doi.org\/10.1093\/nar\/gky1055.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2197_CR24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","volume":"45","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470\u20133. https:\/\/doi.org\/10.1038\/ng.2813.","journal-title":"Nat Genet"},{"issue":"6","key":"2197_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/ng.2273","volume":"44","author":"CK Ong","year":"2012","unstructured":"Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44(6):690\u20133. https:\/\/doi.org\/10.1038\/ng.2273.","journal-title":"Nat Genet"},{"issue":"11","key":"2197_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nri3908","volume":"15","author":"D Vestweber","year":"2015","unstructured":"Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015;15(11):692\u2013704. https:\/\/doi.org\/10.1038\/nri3908.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2197_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315. https:\/\/doi.org\/10.1038\/nm.3541.","journal-title":"Nat Med"},{"issue":"8","key":"2197_CR28","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1172\/JCI93182","volume":"127","author":"K Jung","year":"2017","unstructured":"Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest. 2017;127(8):3039\u201351. https:\/\/doi.org\/10.1172\/JCI93182.","journal-title":"J Clin Invest"},{"issue":"2","key":"2197_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313\u201326. https:\/\/doi.org\/10.1016\/j.cell.2018.09.035.","journal-title":"Cell"},{"issue":"6","key":"2197_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341\u201355. https:\/\/doi.org\/10.1038\/s41571-019-0173-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2197_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12(1):153\u201386. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100322.","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"2197_CR32","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.33013.","journal-title":"Int J Cancer"},{"issue":"1","key":"2197_CR33","doi-asserted-by":"publisher","first-page":"12348","DOI":"10.1038\/s41598-020-69366-4","volume":"10","author":"S Ahn","year":"2020","unstructured":"Ahn S, Lee JC, Shin DW, Kim J, Hwang JH. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10(1):12348. https:\/\/doi.org\/10.1038\/s41598-020-69366-4.","journal-title":"Sci Rep"},{"issue":"6","key":"2197_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0930.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2197_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414\u201324. https:\/\/doi.org\/10.21037\/hbsn-20-338.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"12","key":"2197_CR36","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","volume":"23","author":"HT Arkenau","year":"2018","unstructured":"Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23(12):1407\u2013e136. https:\/\/doi.org\/10.1634\/theoncologist.2018-0044.","journal-title":"Oncologist"},{"issue":"8","key":"2197_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611\u201321. https:\/\/doi.org\/10.1016\/S2468-1253(19)30086-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2197_CR38","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380\u201396. https:\/\/doi.org\/10.1172\/JCI137110.","journal-title":"J Clin Invest"},{"key":"2197_CR39","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2020.38.15_suppl.4520","volume":"38","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Lee K-H, Lee D-W, Kim TY, Bang J-H, Nam A-R, et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \u00b1 tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advanced biliary tract cancer (aBTC). J Clin Oncol. 2020;38:4520.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2197_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019\u201333. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.034.","journal-title":"Mol Cell"},{"issue":"15","key":"2197_CR41","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-19-1321","volume":"26","author":"CS Garris","year":"2020","unstructured":"Garris CS, Luke JJ. Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res. 2020;26(15):3901\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1321.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2197_CR42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2020.10.037","volume":"74","author":"YH Huang","year":"2021","unstructured":"Huang YH, Zhang CZ, Huang QS, Yeong J, Wang F, Yang X, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol. 2021;74(4):838\u201349. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.037.","journal-title":"J Hepatol"},{"issue":"1","key":"2197_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","volume":"6","author":"Y Cao","year":"2021","unstructured":"Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, et al. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther. 2021;6(1):15. https:\/\/doi.org\/10.1038\/s41392-020-00376-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2197_CR44","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, et al. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10(5):723\u201333. https:\/\/doi.org\/10.1016\/j.apsb.2019.09.006.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"2197_CR45","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ejca.2014.01.017","volume":"50","author":"M Wachowska","year":"2014","unstructured":"Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, et al. 5-Aza-2\u2019-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014;50(7):1370\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.017.","journal-title":"Eur J Cancer"},{"issue":"7","key":"2197_CR46","first-page":"1766","volume":"54","author":"J Weber","year":"1994","unstructured":"Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine. Cancer Res. 1994;54(7):1766\u201371.","journal-title":"Cancer Res"},{"issue":"11","key":"2197_CR47","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-06-3091","volume":"13","author":"E Fonsatti","year":"2007","unstructured":"Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2\u2019-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res. 2007;13(11):3333\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3091.","journal-title":"Clin Cancer Res"},{"issue":"7577","key":"2197_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353. https:\/\/doi.org\/10.1038\/nature15520.","journal-title":"Nature"},{"issue":"21","key":"2197_CR49","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-19-0428","volume":"79","author":"H Dong","year":"2019","unstructured":"Dong H, Liu S, Zhang X, Chen S, Kang L, Chen Y, et al. An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response. Cancer Res. 2019;79(21):5587\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0428.","journal-title":"Cancer Res"},{"issue":"2","key":"2197_CR50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","volume":"76","author":"N Nagarsheth","year":"2016","unstructured":"Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 2016;76(2):275\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1938.","journal-title":"Cancer Res"},{"issue":"9","key":"2197_CR51","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1073\/pnas.1914937117","volume":"117","author":"H Jiang","year":"2020","unstructured":"Jiang H, Cao HJ, Ma N, Bao WD, Wang JJ, Chen TW, et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proc Natl Acad Sci U S A. 2020;117(9):4770\u201380. https:\/\/doi.org\/10.1073\/pnas.1914937117.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02197-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02197-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02197-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T14:14:39Z","timestamp":1644243279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02197-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02197-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All collection and usage of human samples and clinical data were in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committee of Eastern Hepatobiliary Surgery Hospital (EHBHKY2018-02-014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants granted consent for the publication of the de-identified result.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Xu, G. Wang, C. Li, Y. Zhang, J. Zhao, C. Wang, X. Wen, Z. Zhang, B. Li, H. Zhang, Z. Zhang, and S. Cai are employees of Burning Rock Biotech. The other authors declare that they have no competing interests..","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}